The Key To Big Pharma Deals: How Korea's ABL Reached $1bn Sanofi Agreement
Science, Data Form Backbone
ABL Bio CEO shares experience from reaching a $1bn licensing deal with Sanofi, why it chose the French giant as its partner, what happened during the negotiation process and the next steps for the Korean company.
You may also be interested in...
German firm’s antibody-drug conjugates use amanitin payload. Plus deals involving Sanwa Kagaku/Crinetics, Takeda/Code Bio, Taro/Alchemee, Mankind/Dr. Reddy’s and more.
Only one last step remains before the approval of South Korea’s first home-grown COVID-19 vaccine as SK Bioscience’s SKYCovione (GBP510) receives positive assessments from review committees. Any nod, which could happen this week, would mark a milestone for the country's ambitions of becoming a global vaccine hub.
Falling foreign investment and increasing business uncertainties in China could present new opportunities for the Korean biopharma sector, which is stepping up globalization and R&D efforts to seek growth.